A recent Dutch cohort study found no evidence for a risk reduction of breast cancer risk in BRCA1/2 mutation carriers after RRSO [hazard ratio 1.09 (95 % CI 0.67–1.77)] and stated that previous data may have overestimated the risk reduction because of bias [12]. This evidence concerns the gene BRCA1 and breast cancer.